Frontida BioPharm, Inc. Names Dr. Ralph Landau President
Frontida Biopharm, Inc is pleased to announce that Dr. Ralph Landau has been appointed to the role of President of Frontida Biopharm, Inc. He will be responsible the operations in both the United States and China.
Frontida BioPharm and Oncoceutics Announce Product Development and Commercialization Partnership
Frontida BioPharm, Inc. and Oncoceutics Inc. announced that the two companies have entered into a product development and commercialization agreement to further develop and scale-up the finished product manufacturing process for ONC201, Oncoceutics’ lead molecule.
Frontida BioPharm acquires Philadelphia & Aurora facilities from Sun Pharmaceuticals
Philadelphia, PA – June 4, 2016: Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, today announced that its affiliate company, Frontida BioPharm, Inc. (“Frontida”) has acquired certain assets from a wholly owned US subsidiary of Sun Pharma.
AdaptDose™, The innovation in drug development, that reduces development time by up to 30%
Frontida’s AdaptDose™ technology platform provides a tool that can eliminate the need to reformulate after Phase I and overcomes several technical hurdles in the development and scale up of (1) new molecules, (2) binary and tertiary mixtures of active ingredients, zero and first order drug release matrices, or (3) scalable clinical trial materials used in dose ranging or adaptive dose clinical studies.
Frontida BioPharm, Inc. a Contract Development and Manufacturing Organization located in Philadelphia, PA and Aurora, IL announces that the Food and Drug Administration ("FDA") has issued a closure letter for its Philadelphia manufacturing site on May 4, 2017.
Frontida BioPharm and TruPharma Finalize Partnership For Marketing of 5 Products
Frontida BioPharm, Inc. a Contract Development and Manufacturing Organization with headquarters in Philadelphia, PA announced that it has entered into an exclusive agreement with TruPharma, LLC to market and distribute five ANDAs.